Business Services Industry

Calypte Biomedical to Present At Wall Street Analyst Forum; Management to Address Analysts, Portfolio Managers On February 14 At Institutional Conference

Business Wire, Feb 12, 2002

Business Editors/Health & Medical Writers

ALAMEDA, Calif.--(BW HealthWire)--Feb. 12, 2002

Calypte Biomedical Corporation (OTCBB:CALY), a public healthcare company dedicated to the development and commercialization of urine-based diagnostic products and services, today announced that its senior management will be making a presentation to analysts and portfolio managers at The Wall Street Analyst Forum's Institutional Investor Conference.

The conference is being held at the Roosevelt Hotel in New York City. The Calypte presentation is scheduled for Thursday, Feb. 14, 2002, at 10:50 a.m., Eastern Time, with additional time available for attendees to meet with Calypte management immediately after the presentation.

Analysts and portfolio managers who wish to attend the presentation should contact Wall Street Analyst Forum at 802/253-7596. The link for the Internet web cast will be available from the company's website at www.calypte.com, or http://media.corporate-ir.net/media_files/priv/wsaf/event/021102.htm.> Calypte Biomedical Corporation, headquartered in Alameda, is a public healthcare company dedicated to the development and commercialization of urine-based diagnostic products and services for Human Immunodeficiency Virus Type 1 (HIV-1), sexually transmitted diseases and other infectious diseases. Calypte's tests include the screening EIA and supplemental Western Blot tests, the only two FDA-approved HIV-1 antibody tests that can be used on urine samples. The company believes that accurate, non-invasive urine-based testing methods for HIV and other infectious diseases may make important contributions to public health by helping to foster an environment in which testing may be done safely, economically, and painlessly. Calypte markets its products in countries worldwide through international distributors and strategic partners.

Statements in this press release that are not historical facts are forward-looking statements, including statements regarding announcements of financial results and presentations by the Company. Such statements reflect management's current views, are based on certain assumptions and involve risks and uncertainties. Actual results, events, or performance may differ materially from the above forward-looking statements due to a number of important factors, and will be dependent upon a variety of factors, including, but not limited to, our ability to obtain additional financing that will allow us to continue our current and future operations and whether demand for our product and testing service in domestic and international markets will continue to expand. The Company undertakes no obligation to publicly update these forward-looking statements to reflect events or circumstances that occur after the date hereof or to reflect any change in the Company's expectations with regard to these forward-looking statements or the occurrence of unanticipated events. Factors that may impact the Company's success are more fully disclosed in the Company's most recent public filings with the U.S. Securities and Exchange Commission ("SEC"), including its annual report on Form 10-K for the year ended December 31, 2000 and its subsequent filings with the SEC.